MP0112

MP0112 is a therapeutic antibody designed to target and inhibit the activity of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF). It is currently under development by Molecular Partners, a Swiss biotechnology company, for the treatment of various cancer types and eye diseases.

Mechanism of Action

MP0112 works by binding to VEGF and HGF, two growth factors that play crucial roles in the development of tumors and angiogenesis. By inhibiting these growth factors, MP0112 can potentially slow down or stop the growth of tumors and the formation of new blood vessels, which are essential for tumor growth and survival.

Clinical Trials

MP0112 is currently in the early stages of clinical trials. Preliminary results have shown promising efficacy and safety profiles in patients with various types of cancer and eye diseases. However, further studies are needed to confirm these findings and to determine the optimal dosing and administration of MP0112.

Potential Applications

In addition to its potential use in cancer therapy, MP0112 may also be used in the treatment of eye diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. These diseases are characterized by abnormal blood vessel growth in the eye, which can lead to vision loss. By inhibiting VEGF and HGF, MP0112 may help to prevent this abnormal blood vessel growth and preserve vision.

See Also

• Therapeutic Antibodies
• Vascular Endothelial Growth Factor
• Hepatocyte Growth Factor
• Molecular Partners
• Cancer
• Eye Diseases